Research
FORUM TRANSCRIPT

China’s Antibody Drug Conjugate R&D & Pharmaceutical Companies’ Competencies – 27 July 2021

  • Private Equity
  • Healthcare
  • Greater China
PREMIUM

Specialist

Executive at Suzhou MediLink Therapeutics Ltd

Agenda

  • Antibody drug conjugate (ADC) R&D barriers – linker technologies, antibody design, cytotoxic payload and conjugation process, plus domestic and foreign pharmaceutical companies’ technology platforms
  • Clinical research challenges, plus China's Center for Drug Evaluation and the US Food and Drug Administration review and approval
  • Anti-TROP-2 and anti-HER2 ADC clinical research progress at home and abroad, plus clinical data analysis
  • R&D team demand and personnel structure, plus domestic and foreign pharmaceutical companies’ team competency comparison

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo